- Home
- GLXG vs DMAC Comparison
GLXG vs DMAC Comparison
Compare GLXG & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLXG
- DMAC
- Stock Information
- Founded
- GLXG 2013
- DMAC 2000
- Country
- GLXG Hong Kong
- DMAC United States
- Employees
- GLXG N/A
- DMAC N/A
- Industry
- GLXG
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- GLXG
- DMAC Health Care
- Exchange
- GLXG NYSE
- DMAC Nasdaq
- Market Cap
- GLXG 70.4M
- DMAC 172.7M
- IPO Year
- GLXG 2024
- DMAC N/A
- Fundamental
- Price
- GLXG $1.81
- DMAC $4.18
- Analyst Decision
- GLXG
- DMAC Strong Buy
- Analyst Count
- GLXG 0
- DMAC 3
- Target Price
- GLXG N/A
- DMAC $7.00
- AVG Volume (30 Days)
- GLXG 856.6K
- DMAC 46.2K
- Earning Date
- GLXG 12-03-2024
- DMAC 11-13-2024
- Dividend Yield
- GLXG N/A
- DMAC N/A
- EPS Growth
- GLXG N/A
- DMAC N/A
- EPS
- GLXG 0.04
- DMAC N/A
- Revenue
- GLXG $3,858,088.00
- DMAC N/A
- Revenue This Year
- GLXG N/A
- DMAC N/A
- Revenue Next Year
- GLXG N/A
- DMAC N/A
- P/E Ratio
- GLXG $88.73
- DMAC N/A
- Revenue Growth
- GLXG N/A
- DMAC N/A
- 52 Week Low
- GLXG $1.51
- DMAC $2.14
- 52 Week High
- GLXG $16.93
- DMAC $4.95
- Technical
- Relative Strength Index (RSI)
- GLXG N/A
- DMAC 48.23
- Support Level
- GLXG N/A
- DMAC $3.96
- Resistance Level
- GLXG N/A
- DMAC $4.21
- Average True Range (ATR)
- GLXG 0.00
- DMAC 0.18
- MACD
- GLXG 0.00
- DMAC -0.02
- Stochastic Oscillator
- GLXG 0.00
- DMAC 50.00
About GLXG GALAXY PAYROLL GROUP LTD
Galaxy Payroll Group Ltd provides payroll outsourcing, employment, consultancy, and market research services based in Hong Kong. Its client base includes retail, trading, industrial, IT, financial, and professional services industries. Geographically, the company derives maximum revenue from its clients in the People's Republic of China and the rest from Hong Kong, Macau, Taiwan, Japan, Thailand, Singapore, and other countries.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.